[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100629243":3},{"organization":4,"outcomesModule":7,"designInfo":29,"detailedDescription":15,"studyPopulation":15,"armGroups":35,"interventions":45,"overallOfficials":15,"centralContacts":55,"locations":64,"responsibleParty":81,"collaborators":15,"id":83,"slug":84,"hasResults":85,"nctId":86,"briefTitle":87,"officialTitle":88,"acronym":15,"eligibilityCriteria":89,"healthyVolunteers":85,"sex":90,"minAge":91,"maxAge":92,"enrollmentInfo":93,"targetDuration":15,"studyType":96,"phases":97,"briefSummary":100,"conditions":101,"keywords":15,"overallStatus":67,"whyStopped":15,"lastUpdateSubmitDate":105,"lastUpdatePostDateStruct":106,"startDateStruct":109,"completionDateStruct":111,"leadSponsor":113,"locationsCount":114},{"fullName":5,"class":6},"N.N. Alexandrov National Cancer Centre","OTHER_GOV",{"primaryOutcomes":8,"secondaryOutcomes":17,"otherOutcomes":15},[9,13],{"measure":10,"description":11,"timeFrame":12},"Disease-free survival","Time from randomization to any sign or symptom of the cancer or death from the disease","From enrollment through study completion, an average of 2 year",{"measure":14,"description":15,"timeFrame":16},"The frequency of adverse events",null,"From date of first immunotherapy dose through 60 months, or date of last patient contact",[18,22,25],{"measure":19,"description":20,"timeFrame":21},"Disease-free survival 2","Time from the first recurrence when patient remains free of cancer signs or symptoms to any sign or symptom of the cancer or death from the disease","From the first recurrence through study completion, an average of 2 year",{"measure":23,"description":24,"timeFrame":12},"Time from Randomization to First Subsequent Therapy","Time from randomization to the initiation of the next (second-line) therapy, most often due to disease progression.",{"measure":26,"description":27,"timeFrame":28},"The quality of life","Assessment of quality of life using the European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire Core 30 (EORTC QLQ-C30). Scales range from 0 to 100; higher scores indicate better outcomes on functional and global health scales, but worse outcomes on symptom scales","Through study completion, an average of 5 year",{"allocation":30,"interventionModel":31,"interventionModelDescription":15,"primaryPurpose":32,"observationalModel":15,"timePerspective":15,"maskingInfo":33},"RANDOMIZED","PARALLEL","TREATMENT",{"masking":34,"maskingDescription":15,"whoMasked":15},"NONE",[36,41],{"label":37,"type":38,"description":15,"interventionNames":39},"PARPi + Bev","EXPERIMENTAL",[40],"Drug: PARP inhibitor + Bevacizumab",{"label":42,"type":38,"description":15,"interventionNames":43},"PARPi",[44],"Drug: PARP inhibitor",[46,51],{"type":47,"name":48,"description":49,"armGroupLabels":50,"otherNames":15},"DRUG","PARP inhibitor + Bevacizumab","Patients will receive 6 courses of chemotherapy according to the regimen of platinum drug + paclitaxel + bevacizumab (≥3 cycles) every 21 days. In case of a complete or partial response maintenance therapy is carried out until disease progression or intolerable toxicity or for 2 years to the regimen of PARP inhibitor + bevacizumab.",[37],{"type":47,"name":52,"description":53,"armGroupLabels":54,"otherNames":15},"PARP inhibitor","Patients will receive 6 courses of chemotherapy according to the regimen of platinum drug + paclitaxel every 21 days. In case of a complete or partial response maintenance therapy of PARP inhibitor is carried out until disease progression or intolerable toxicity or for 2 years.",[42],[56,61],{"name":57,"role":58,"phone":59,"phoneExt":15,"email":60},"Hanna Trukhan","CONTACT","80291985715","annavladimir@rambler.ru",{"name":62,"role":58,"phone":15,"phoneExt":15,"email":63},"Sergey Mavrichev","smavrichev71@gmail.com",[65],{"facility":66,"status":67,"city":68,"state":69,"zip":70,"country":71,"countryCode":72,"cosmosGeoPoint":73,"geoPoint":78,"contacts":79},"N.N. Alexandrov National Caner Centre","RECRUITING","Minsk","Lesnoy","223040","Belarus","BY",{"type":74,"coordinates":75},"Point",[76,77],27.56653,53.90019,{"lat":77,"lon":76},[80],{"name":57,"role":58,"phone":59,"phoneExt":15,"email":60},{"type":82,"investigatorFullName":15,"investigatorTitle":15,"investigatorAffiliation":15,"oldNameTitle":15,"oldOrganization":15},"SPONSOR","100629243","phase-2-parp-poly-adp-ribose-polymerase-inhibitor-with-or-without-angiogenesis-inhibitor-in-homologous-recombination-deficient-primary-ovarian-cancer-fallopian-tube-cancer-or-primary-peritoneal-cancer-100629243",false,"NCT07472140","PARP (Poly (ADP-ribose) Polymerase) Inhibitor With or Without Angiogenesis Inhibitor in Homologous Recombination Deficient Primary Ovarian Cancer, Fallopian-Tube Cancer, or Primary Peritoneal Cancer","To Develop and Implement The Scope of Medical Care for Homologous Recombination Deficient Ovarian Cancer, Fallopian-Tube Cancer, or Primary Peritoneal Cancer of the III-IV Stages Using Maintenance Therapy With PARP Inhibitor Combined With Angiogenesis Inhibitor.","Inclusion Criteria:\n\n* Age ≥18-≤75 years.\n* Histologically confirmed diagnosis of serous or endometrioid high-grade ovarian cancer, fallopian-tube cancer or primary peritoneal cancer.\n* Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.\n* Possibility of performing diagnostic laparoscopy or cytoreductive surgery.\n* Presence of homologous recombination deficiency (HRD).\n* No contraindications to chemotherapy, or bevacizumab.\n* Signed informed consent to participate in the study.\n\nExclusion Criteria:\n\n* Presence of another active malignant invasive neoplasm.\n* Pregnancy or lactation period.\n* Disease progression during treatment.","FEMALE","18 Years","75 Years",{"count":94,"type":95},120,"ESTIMATED","INTERVENTIONAL",[98,99],"PHASE2","PHASE3","This is a randomized trial evaluating the results of using of PARP inhibitor combined with angiogenesis inhibitor. in patients with homologous recombination deficient primary ovarian cancer, fallopian-tube cancer, or primary peritoneal cancer of the III-IV stages.",[102,103,104],"Ovarian Cancer","Fallopian Tube Cancers","Primary Peritoneal Cancer","2026-03-11",{"date":107,"type":108},"2026-03-16","ACTUAL",{"date":110,"type":108},"2025-07-01",{"date":112,"type":95},"2033-06-30",{"name":5,"class":6},1]